C Etherington1, R Naseer2, S P Conway2, P Whitaker2, M Denton3, D G Peckham2. 1. Regional Adult Cystic Fibrosis Unit, St James's University Hospital, Beckett Street, Leeds LS9 7TF, United Kingdom. Electronic address: christine.etherington@leedsth.nhs.uk. 2. Regional Adult Cystic Fibrosis Unit, St James's University Hospital, Beckett Street, Leeds LS9 7TF, United Kingdom. 3. Microbiology Department, Leeds General Infirmary, Great George Street, Leeds LS1 3BR, United Kingdom.
Abstract
BACKGROUND: Respiratory viruses have become increasingly recognised as important agents in pulmonary exacerbations in infants and children with CF. The aim of this study was to determine the prevalence of respiratory viruses during acute pulmonary exacerbations in adults and compare the severity of these exacerbations with non-viral associated exacerbations. METHODS: This was a retrospective case control study. Viral throat swabs were taken from all patients presenting with an acute pulmonary exacerbation requiring intravenous antibiotic treatment over a 12 month period. RESULTS: There were 432 pulmonary exacerbations in 180 adults. A positive viral PCR in 42 exacerbations indicated a prevalence of 9.7%. The commonest virus isolated was rhinovirus (n = 29, 69%) with influenza A/H1N1 in seven patients (16.7%). Exacerbations associated with a positive viral PCR had a greater fall in lung function at presentation with higher levels of inflammatory markers. They received more days of intravenous antibiotics, showed less response to treatment and had a shorter time to next pulmonary exacerbation compared to matched controls. CONCLUSION: Viral associated pulmonary exacerbations in adults with CF are associated with more severe pulmonary involvement and respond less well to standard treatment.
BACKGROUND:Respiratory viruses have become increasingly recognised as important agents in pulmonary exacerbations in infants and children with CF. The aim of this study was to determine the prevalence of respiratory viruses during acute pulmonary exacerbations in adults and compare the severity of these exacerbations with non-viral associated exacerbations. METHODS: This was a retrospective case control study. Viral throat swabs were taken from all patients presenting with an acute pulmonary exacerbation requiring intravenous antibiotic treatment over a 12 month period. RESULTS: There were 432 pulmonary exacerbations in 180 adults. A positive viral PCR in 42 exacerbations indicated a prevalence of 9.7%. The commonest virus isolated was rhinovirus (n = 29, 69%) with influenza A/H1N1 in seven patients (16.7%). Exacerbations associated with a positive viral PCR had a greater fall in lung function at presentation with higher levels of inflammatory markers. They received more days of intravenous antibiotics, showed less response to treatment and had a shorter time to next pulmonary exacerbation compared to matched controls. CONCLUSION: Viral associated pulmonary exacerbations in adults with CF are associated with more severe pulmonary involvement and respond less well to standard treatment.
Authors: Ixsy A Ramirez; Lindsay J Caverly; Lindsay L Caverly; Linda M Kalikin; Adam M Goldsmith; Toby C Lewis; David T Burke; John J LiPuma; Uma S Sajjan; Marc B Hershenson Journal: Ann Am Thorac Soc Date: 2014-05
Authors: Andrea N Faris; Shyamala Ganesan; Asamanja Chattoraj; Sangbrita S Chattoraj; Adam T Comstock; Benjamin L Unger; Marc B Hershenson; Umadevi S Sajjan Journal: Am J Respir Cell Mol Biol Date: 2016-10 Impact factor: 6.914
Authors: Sara Khanal; Megan Webster; Naiqian Niu; Jana Zielonka; Myra Nunez; Geoffrey Chupp; Martin D Slade; Lauren Cohn; Maor Sauler; Jose L Gomez; Robert Tarran; Lokesh Sharma; Charles S Dela Cruz; Marie Egan; Theresa Laguna; Clemente J Britto Journal: Eur Respir J Date: 2021-11-11 Impact factor: 33.795
Authors: John C Lam; Ranjani Somayaji; Michael G Surette; Harvey R Rabin; Michael D Parkins Journal: BMC Infect Dis Date: 2015-03-22 Impact factor: 3.090
Authors: Lisa A Carmody; Jiangchao Zhao; Linda M Kalikin; William LeBar; Richard H Simon; Arvind Venkataraman; Thomas M Schmidt; Zaid Abdo; Patrick D Schloss; John J LiPuma Journal: Microbiome Date: 2015-04-01 Impact factor: 14.650
Authors: Gabriella Wojewodka; Juan B De Sanctis; Joanie Bernier; Julie Bérubé; Heather G Ahlgren; Jim Gruber; Jennifer Landry; Larry C Lands; Dao Nguyen; Simon Rousseau; Andrea Benedetti; Elias Matouk; Danuta Radzioch Journal: PLoS One Date: 2014-02-12 Impact factor: 3.240
Authors: Kate Skolnik; Austin Nguyen; Ranjani Somayaji; Christina S Thornton; Barbara Waddell; Michael G Surette; Harvey R Rabin; Michael D Parkins Journal: BMC Pulm Med Date: 2015-12-12 Impact factor: 3.317